The prenylation of several proteins involved in oncogenesis and signal transduction plays an essential role in regulating their biological activities. Two distinct isoprenoids are known to be involved in this modification, the 15-carbon farnesyl and 20-carbon geranylgeranyl groups. Thus far, identified farnesylated proteins contain methionine or serine at the COOH terminus, while those modified by geranylgeranyl end in leucine. This report describes the characterization of an enzyme activity that transfers the geranylgeranyl group to candidate proteins. The enzyme, termed a "protein geranylgeranyltransferase," exhibits a marked preference for substrate proteins that contain leucine at the COOH terminus. In fact, the enzyme will efficiently modify a normally farnesylated protein, Ha-ras, if its COOH-terminal amino acid is switched from serine to leucine. Additional studies characterize this enzyme and suggest that it is responsible for the geranylgeranyl modification of a number of GTP-binding proteins (or their subunits) that contain a consensus prenylation sequence ending in leucine.
great deal of interest in determining both the mechanistic details of protein prenylation and the functional properties imparted by these modifications. The first step in these investigations is the isolation and characterization of the enzymes (protein prenyltransferases) that carry out protein prenylation. The first such enzyme, a protein farnesyltransferase (farnesyltransferase) capable of modifying the ras proteins, has been identified and isolated (16, 17) . This enzyme has the capacity to recognize short peptides containing the Cys-AAX motif, enabling a detailed analysis ofthe sequence requirements for farnesylation (16, 18) . However, the farnesyltransferase poorly recognizes peptides containing the Cys-AAX motif of known geranylgeranylated proteins, suggesting that a separate enzyme is responsible for this modification. In this report we identify this enzyme, termed a "protein geranylgeranyltransferase" (GerGertransferase), and document properties of the enzyme that should greatly facilitate investigation of the role of protein prenylation in oncogenesis and signal transduction.
The covalent modification of proteins by isoprenoid lipids (prenylation) is now recognized as a mechanism to promote membrane interactions and biological activities of these proteins (1, 2) . Both farnesyl (15-carbon) and geranylgeranyl (20-carbon) isoprenoids are involved in these modifications. Known farnesylated proteins include the ras protooncogene products, for which prenylation is required for expression of oncogenic potential (3) (4) (5) , and the nuclear protein lamin B (6, 7) . The geranylgeranyl group has been found on the y subunits (GY subunits) of some signal-transducing GTP- binding proteins (G proteins) (8, 9) and at least three members of the family of "small" GTP-binding proteins (10) (11) (12) . This latter group includes the raplA protein, which is of particular interest because of its ability to reverse ras-induced transformation of cells (13) .
The current consensus sequence for prenylation includes an invariant cysteine residue, initially four residues from the COOH terminus of the protein, to which the prenyl group is attached. This region has been dubbed the "Cys-AAX motif," where the A (aliphatic) and X (initially undefined) residues specify amino acids that are removed following prenylation, freeing the COOH group of the modified cysteine residue for methylation (14, 15) . The studies noted above suggest that it is the COOH-terminal residue (X) that defines which isoprenoid will be added to the protein, as methionine or serine at this position appears to dictate farnesyl addition whereas leucine signals a geranylgeranyl modification (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Since it may be possible to control the processing and biological activities of the ras and related proteins by using specific inhibitors of the prenylation machinery, there is a EXPERIMENTAL PROCEDURES Expression and Purification of Recombinant Proteins. The ras-Cys-Val-Leu-Leu construct (ras-CVLL; in which the Ha-ras COOH-terminal residue serine has been replaced by leucine) and raplA construct, in expression vectors based on pXVR (19) , were obtained from Channing Der (La Jolla Cancer Research Foundation, CA). The plasmids were transformed into Escherichia coli strain PR13Q. Protein production was induced, and extracts were prepared and separated into soluble and insoluble fractions. The recombinant proteins were purified from the insoluble fraction (R. Deloskey and S. Burk, personal communication), which contained the bulk of the ras-CVLL or raplA, apparently in inclusion bodies. Briefly, the insoluble fraction obtained from a 1-liter culture of cells was extracted with 10 ml of 3.5 M guanidinehydrochloride, and the extract was rapidly diluted to 500 ml with an ice-cold buffer consisting of 50 mM Tris chloride (pH 8.0), 1 mM EDTA, 1 mM dithiothreitol, 3 mM MgCl2, and 10 tuM GDP. After a 1-hr incubation at 2TC, this mixture was centrifuged at 30,000 x g for 1 hr, and the superatant was chromatographed on DEAE-Sephacel as described (16) . ras-CVLL was eluted at z200 mM NaCl from this column, while raplA did not adsorb and was recovered from the flowthrough fraction. The proteins were identified by both SDS/ PAGE analysis and GTP-binding activity. The protein pools were concentrated to -3 mg/ml in a Centriprep 10 concentrator, flash-frozen in multiple aliquots, and stored at -70'C.
Abbreviations: GerGer-transferase, protein geranylgeranyltransferase; ras-CVLL, Ha-ras in which the COOH-terminal residue serine has been replaced by leucine; G protein, GTP-binding protein;
GIsubunit, -y subunit of G protein; farnesyltransferase, protein famesyltransferase.
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The Ha-ras protein was purified from a bacterial expression system as described (16) .
Purification of GerGer-Transferase. An extract was prepared from five bovine brains as described for a similar preparation from rat brains (16) and centrifuged for 90 min at 30,000 x g. The resulting supernatant fraction (2500 ml) was flash-frozen by pouring into liquid nitrogen and stored at -800C until use.
Six hundred milliliters of the supernatant obtained at high speed from the bovine brain extract was chromatographed on a 5.0 x 25 cm column of DEAE-Sephacel (Pharmacia). The column, equilibrated in 50 mM Tris chloride, pH 8.0/1 mM EDTA/1 mM dithiothreitol (buffer A) containing 0.2 mM phenylmethylsulfonyl fluoride, was washed with 500 ml of the same buffer and then eluted with a gradient of 2 liters of 0-500 mM NaCl in the same buffer. Fractions of 22 ml were collected. The fractions containing the peak of GerGertransferase activity (fractions 42-55 in Fig. 1 Upper) were pooled, concentrated, and chromatographed on a 5.0 x 40 cm column of AcA34 resin (Spectrum Laboratories, Houston) in buffer A containing 100 mM NaCl. Fractions of 9 ml were collected. The peak fractions from the AcA column (fractions 47-55) were pooled, concentrated to 20 ml, dialyzed against buffer A, and chromatographed on a Mono-Q HR 10/10 column (Pharmacia) equilibrated in buffer A. The column was o-C washed with 10 ml ofthe same buffer and eluted with a 100-ml gradient of 0-400 mM NaCl in buffer A (see Fig. 1 GerGer-transferase was purified from the supernatant from high-speed centrifugation of a bovine brain extract by sequential chromatography on DEAE, AcA34 gel filtration, and fast protein liquid chromatography Mono-Q resins. The DEAE chromatographic step provided good resolution of GerGer-transferase and farnesyltransferase activities ( Fig. 1 Upper); this provided direct evidence that the two protein prenyltransferase activities reside on distinct proteins. The peak of GerGer-transferase activity from the DEAE column ( Fig. 1 Upper) was further fractionated on the AcA34 resin, where both the GerGer-transferase and the small amount of contaminating farnesyltransferase comigrated (not shown). However, this remaining farnesyltransferase activity was completely resolved from GerGer-transferase by chromatography on Mono-Q resin (Fig. 1 Lower) . This Mono-Q-purified material ("resolved GerGer-transferase") was used for all subsequent studies. This entire purification procedure has been repeated three times and consistently results in a preparation of resolved GerGer-transferase with a specific activity of 500-700 pmol hr-i'(mg of protein)-', representing a 100-to 140-fold increase over the starting material, with overall yields from 50% to 60%o. The enzyme displays Michaelis-Menten-type kinetics toward the prenyl substrate, with an apparent Km of 0.3 uM for geranylgeranyl pyrophosphate, and has a pH optimum in the slightly basic range, with maximal activity being observed from pH 7.5 to pH 8.5 (not shown).
Mono-Q chromatography of the farnesyltransferase pool obtained from the DEAE column (Figure 1 Upper, fractions 56-66), when performed under identical conditions to those used for GerGer-transferase ( Fig. 1 Lower), resulted in a complete separation of this activity from GerGer-transferase (not shown). This "resolved farnesyltransferase" exhibited a specific activity of 3000 pmol hr-'(mg of protein)-71 and was used in studies described below comparing the specificities of the two protein prenyltransferases.
Under our standard conditions, the resolved GerGertransferase modified both the ras-CVLL and raplA proteins, but apparently not Ha-ras, in reactions dependent on both the recombinant protein and metal ions (Fig. 2) . Chemical analysis of the prenyl group attached to the acceptor proteins in these assays (21) verified that it was the geranylgeranyl group (not shown).
For a further analysis of the ability of the resolved GerGertransferase to discriminate between Ha-ras and ras-CVLL, which differ in only their COOH-terminal residue, we examined the protein substrate dependence of both of the resolved protein prenyltransferases (Fig. 3) . Consistent with the results in Fig. 2 GerGer-transferase with an apparent Km of 1.5 juM, while substrate activity with Ha-ras was barely detectable (Fig. 3 Upper). Essentially converse results were obtained with the farnesyltransferase, which accepted Ha-ras as a substrate with an apparent Km of 8 ,AM, while activity with the ras-CVLL protein was very poor (Fig. 3 Lower) .
A more detailed examination of the substrate specificities of the two protein prenyltransferases is shown in Fig. 4 , where each enzyme was assayed with the four possible combinations of protein and prenyl substrates. As expected from the results described above, each protein prenyltransferase shows a marked preference for its "correct" substrates (GerGer-transferase, ras-CVLL and geranylgeranyl pyrophosphate; farnesyltransferase, Ha-ras and farnesyl pyrophosphate), although there was a small, but detectable, activity in some of the other conditions.
Like the farnesyltransferase, the resolved GerGertransferase has the capacity to recognize short peptides that encompass the Cys-AAX prenylation consensus sequence (Fig. 5 Upper) . In particular, we have studied the decapeptide corresponding to the COOH terminus of the brain G.
subunit, synthesized with a tyrosine residue at the NH2 terminus (Tyr-Arg-Glu-Lys-Lys-Phe-Phe-Cys-Ala-Ile-Leu) to facilitate future studies, and the undecapeptide corresponding to the COOH terminus ofthe small G protein, G25K (Glu-Pro-Lys-Lys-Ser-Arg-Arg-Cys-Val-Leu-Leu). For comparison, the decapeptide of the COOH-terminal portion of a known farnesylated protein (3) , Ki-ras (Lys-Lys-SerLys-Thr-Lys-Cys-Val-Ile-Met), was also analyzed. While 
DISCUSSION
The observations reported here will have an important impact on studies involving the role of protein prenylation in oncogenesis and signal transduction. The availability of the GerGer-transferase will allow an analysis of its mechanism of action and facilitate discovery and development of inhibitors specific to each class (farnesyl and geranylgeranyl) of protein prenyltransferase. This is especially important -given the increasing interest in such inhibitors as possible therapeutic agents in the treatment of human cancers (24, 25) . Furthermore, comparisons of the structural relationships of the two classes of protein prenyltransferases have already begun (26) and have revealed that they share a highly related, if not identical, subunit.
These results also underscore the importance of the COOH-terminal residue of prenylated proteins in determining which isoprenoid will be attached. Thus, it appears that a single amino acid change is all that will be required in cDNA expression studies designed to examine the influence of isoprenoid chain length on prianyl protein targeting and function in intact cells. Since the final three amino acids of these proteins are proteolytically removed after prenylation, the mature protein produced after expression of an altered cDNA should be identical to its wild-type counterpart with the exception ofthe isoprenoid attached. However, since the relationship of the in vitro and in vivo specificities of the protein prenyltransferases is not yet known, the analysis of experiments conducted in intact cells may still be compli- This paper is dedicated to Dr. Robert Abeles on the occasion of his 65th birthday. We thank S. Garrett for helpful comments on the manuscript, and C. J. Der for the ras and raplA expression plasmids. This work was supported in part by a grant from the American Cancer Society (IN-158C) to the Duke Comprehensive Cancer Center.
